PRESS RELEASE

Partner Magenta Therapeutics Presents Preclinical Data on Lead Clinical Candidate MGTA-117 Demonstrating Broad Tolerability and High Therapeutic Index

- Preclinical data from Magenta’s newest clinical candidate, MGTA-117, were presented at the 2020 TCT - Transplantation & Cellular Therapy Meeting in Orlando
- MGTA-117 demonstrates broad tolerability and high therapeutic index

Ladenburg, Germany, 24 February 2020 – Heidelberg Pharma AG (FSE: WL6) today announced that its partner Magenta Therapeutics (NASDAQ: MGTA), Cambridge, MA, USA, (Magenta), has unveiled MGTA-117 as a clinical candidate for targeted patient preparation for stem cell transplant or gene therapy (conditioning) and presented preclinical data. MGTA-117 is an Antibody Targeted Amanitin Conjugate (ATAC) consisting of a CD117 antibody and Amanitin as payload. It was developed under a partnership with Heidelberg Pharma that grants Magenta exclusive worldwide development and marketing rights for antibody-drug conjugates using an Amanitin payload and targeting CD117.

New preclinical results show that MGTA-117 potently depleted stem and progenitor cells in comparison to current standard therapies and demonstrated a wide tolerability. MGTA-117 demonstrated potent cytotoxicity on target disease-causing cells and robust anti-tumor activity in xenograft models. The therapeutic index, a measure of drug safety as the ratio of maximum tolerated dose to effective dose, was significantly higher than for other antibody-drug conjugates at this stage of development. This program is now advancing toward the clinic and further validates Magenta’s antibody-drug conjugate-based conditioning platform. The data indicate that conjugates based on Heidelberg Pharma's ATAC technology could be used to prepare patients for immune reset through gene therapies and stem cell transplant. Initial clinical data of MGTA-117 are expected in 2021.

Andreas Pahl, Chief Scientific Officer of Heidelberg Pharma, comments: "We are absolutely delighted and congratulate Magenta on these results, which are further preclinical validation of MGTA-117 in terms of safety, tolerability and efficacy. Our partnership is progressing very successfully and dynamically. We will be excited to follow the clinical development of this important medicine for targeted conditioning before immune reset."

About Magenta Therapeutics

Headquartered in Cambridge, Mass., Magenta Therapeutics is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune diseases, blood cancers and genetic diseases. By creating a platform focused on critical
areas of unmet need, Magenta Therapeutics is pioneering an integrated approach to allow more patients to receive one-time, curative immune reset.

**About Heidelberg Pharma's proprietary ATAC technology**

Antibody drug conjugates (ADCs) combine the high affinity and specificity of antibodies with the potency of cytotoxic small molecules for the treatment of cancer. Antibody Targeted Amanitin Conjugates (ATACs) are ADCs whose active ingredient is made up of amatoxin molecules. Amatoxins are small bicyclic peptides naturally occurring in the death cap mushroom. They inhibit mRNA transcription by binding to RNA polymerase II, a mechanism that is crucial for the survival of eukaryotic cells. In preclinical testing, ATACs have been shown to be highly efficacious, overcoming frequently encountered resistance mechanisms and combating even quiescent tumor cells.

**About Heidelberg Pharma**

Heidelberg Pharma AG is a biopharmaceutical company based in Ladenburg, Germany. Heidelberg Pharma is an oncology specialist and the first company to develop the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology and to advance the biological mode of action of the toxin as a novel therapeutic principle. This proprietary technology platform is being applied to develop the Company's proprietary therapeutic ATACs, as well as in third-party collaborations, to create a variety of ATAC candidates. The proprietary lead candidate is HDP-101, a BCMA ATAC for multiple myeloma. Heidelberg Pharma AG is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol WL6. More information is available at [www.heidelberg-pharma.com](http://www.heidelberg-pharma.com).

**Contact**

Heidelberg Pharma AG  
Corporate Communications  
Sylvia Wimmer  
Tel.: +49 89 41 31 38-29  
Email: investors[at]hdpharma.com  
Schriesheimer Str. 101, 68526 Ladenburg

**IR/PR support**

MC Services AG  
Katja Arnold (CIRO)  
Managing Director & Partner  
Tel.: +49 89 210 228-40  
Email: katja.arnold[at]mc-services.eu

This communication contains certain forward-looking statements relating to the Company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "will" "should" "future", "potential" or similar expressions or by a general discussion of the Company's strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.